National Cancer Institute (NCI): Neoplasm Metastasis trials

The registry lists 121 Neoplasm Metastasis studies with National Cancer Institute (NCI) as lead sponsor. 19 are open to participants now and 34 have results posted.

Early Phase 1 2Phase 1 81Phase 2 48No phase 6(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00021164Phase 2
• Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate CancerTerminatedNCT00019695Phase 2
• Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium BacteriaCompletedNCT00004988Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Oxaliplatin in Cancer Patients With Impaired Kidney FunctionCompletedNCT00001835Phase 1
• Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal SequenceCompletedNCT00001705Phase 2
• Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and TyrosinaseCompletedNCT00001685Phase 2
• A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic CancerCompletedNCT00001683Phase 1
• A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the LiverCompletedNCT00001587Phase 1
• A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the LiverCompletedNCT00001576Phase 1
• A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal CancerCompletedNCT00001570Phase 1
• Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast CancerCompletedNCT00001507Phase 1
• Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast CancerCompletedNCT00001493Phase 2
• Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive ChemotherapyCompletedNCT00001440Phase 1
• A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With OsteosarcomaCompletedNCT00001436Phase 1
• A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833CompletedNCT00001302Phase 1
• Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and LymphomaCompletedNCT00001270Phase 1
• Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast CancerCompletedNCT00001269Phase 1
• Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized TrialCompletedNCT00001250Phase 2
• A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast CancerCompletedNCT00001193Phase 2